Progenics Form S-3 Goldberg shelf Jan 9, 2006
As
filed
with the Securities and Exchange Commission on January 9, 2006
Registration
No. 333-____
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
S-3
REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933
PROGENICS
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or other jurisdiction
of
incorporation or organization)
|
2834
(Primary
Standard
Industrial
Classification Code
Number)
|
13-3379479
(I.
R. S. Employer
Identification
No. )
|
|
777
Old Saw Mill River Road
Tarrytown,
New York 10591
(914)
789-2800
|
|
(Address,
including zip code, and telephone number, including
area
code, of registrant’s principal executive offices)
|
|
Paul
J. Maddon, M.D., Ph.D.
Chief
Executive Officer and
Chief
Science Officer
Progenics
Pharmaceuticals, Inc.
777
Old Saw Mill River Road
Tarrytown,
New York 10591
(914)
789-2800
|
|
(Name,
address, including zip code, and telephone number,
including
area code, of agent for service)
|
|
Copies
to:
|
|
Mark
R. Baker, Esq.
Senior
Vice President and
General
Counsel
Progenics
Pharmaceuticals, Inc.
777
Old Saw Mill River Road
Tarrytown,
New York 10591
(914)
789-2800
|
|
Donald
J. Murray, Esq.
Dewey
Ballantine LLP
1301
Avenue of the Americas
New
York, New York 10019
(212)
259-8000
|
Approximate
date of commencement of proposed sale to the public: As soon as practicable
after this Registration Statement becomes effective.
If
the only securities being registered on this form are being offered pursuant
to
dividend or interest reinvestment plans, please, check the following box: o
If
any of the securities being registered on this form are to be offered on a
delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other
than securities offered only in connection with dividend or interest
reinvestment plans, check the following box:
x
If
this form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act,
please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same
offering. o
If
this form is a post-effective amendment filed pursuant to Rule 462(c) under
the
Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same
offering. o
If
this Form is a registration statement pursuant to General Instruction I.D.
or a
post-effective amendment thereto that shall become effective upon filing with
the Commission pursuant to Rule 462(e) under the Securities Act, check the
following box. o
If
this Form is a post-effective amendment to a registration statement filed
pursuant to General Instruction I.D. filed to register additional securities
or
additional classes of securities pursuant to Rule 413(b) under the Securities
Act, check the following box. o
________________________
CALCULATION
OF REGISTRATION FEE
Title
of Each Class of
Securities
To Be Registered
|
Amount
to be Registered (1)
|
Proposed
Maximum Offering Price Per Unit(2)
|
Proposed
Maximum Aggregate Offering Price(2)
|
Amount
of Registration Fee
|
Common
Stock
($0.0013
par value per share)
|
186,000
|
$26.74
|
$4,973,640
|
$532.18
|
(1)
|
All
of the shares of common stock offered hereby are being offered for
the
account of selling stockholders.
|
(2)
|
Estimated
solely for the purpose of calculating the registration fee in accordance
with Rule 457(c) under the Securities Act of 1933, as amended, and
based
on the average of the high and low prices of the common stock as
reported
on The Nasdaq National Market on January 5,
2006.
|
The
registrant hereby amends this Registration Statement on such date or dates
as
may be necessary to delay its effective date until the registrant shall file
a
further amendment which specifically states that this Registration Statement
shall thereafter become effective in accordance with Section 8(a) of the
Securities Act of 1933 or until this Registration Statement shall become
effective on such date as the Commission, acting pursuant to said Section 8(a),
may determine.
The
information contained in this prospectus is not complete and may be changed.
These securities may not be sold until the registration statement filed with
the
Securities and Exchange Commission is effective. This prospectus is not an
offer
to sell these securities, and it is not soliciting an offer to buy these
securities, in any state where the offer or sale is not
permitted.
SUBJECT
TO COMPLETION, DATED JANUARY 9, 2006
PRELIMINARY
PROSPECTUS
|
Progenics
Pharmaceuticals Inc.
186,000
Shares
Common
Stock
|
This
prospectus relates to the resale from time to time of up to 186,000 shares
of
our common stock, par value $.0013 per share, by the selling stockholders
described in the section entitled “Selling Stockholders” in this prospectus. The
selling stockholders may offer and sell any of the shares of common stock from
time to time at fixed prices, at market prices or at negotiated prices, and
may
engage a broker, dealer or underwriter to sell the shares. For additional
information on the possible methods of sale that may be used by the selling
stockholders, you should refer to the section entitled “Plan of Distribution” in
this prospectus.
The
selling stockholders will receive all of the net proceeds from the sale of
their
shares of our common stock.
We
have
agreed to pay all expenses of registration incurred in connection with this
offering, except any underwriting discounts and commissions and expenses
incurred by the selling stockholders for brokerage, accounting, tax or legal
services or any other expenses that the selling stockholders incur in disposing
of the shares.
Our
common stock is listed on The Nasdaq National Market under the symbol “PGNX.” On
January 6, 2006, the last sales price of our common stock as reported on The
Nasdaq National Market was $29.25 per share.
Investing
in our common stock involves a high degree of risk. See “Risk Factors” beginning
on page 1.
________________________
Neither
the Securities and Exchange Commission nor any state securities commission
has
approved or disapproved these securities or determined if this prospectus or
any
accompanying prospectus supplement is truthful or complete. Any representation
to the contrary is a criminal offense.
________________________
The
date
of this prospectus
is ,
2006 .
Page
|
1
|
|
1
|
|
1
|
|
13
|
|
13
|
|
13
|
|
14
|
|
15
|
|
15
|
|
15
|
You
should rely only on the information contained in this prospectus and any
accompanying prospectus supplement. We and the selling stockholders have not
authorized anyone to provide you with different information. We and the selling
stockholders are not making an offer of these securities in any state where
the
offer is not permitted. You should not assume that the information contained
in
this prospectus and any accompanying prospectus supplement is accurate as of
any
date other than the date on the front cover of those
documents.
This
prospectus is part of a registration statement that we filed with the Securities
and Exchange Commission using a “shelf” registration process. Under this
registration statement, the selling stockholders listed in the selling
stockholder table included in this prospectus may from time to time offer and
sell up to 186,000 shares of our common stock owned by them, at prices and
on
terms to be determined at or prior to the time of sale. This prospectus and
any
applicable prospectus supplement contain information you should know before
investing, including important information about us and our common stock being
offered. You should read both the prospectus and any applicable prospectus
supplement as well as the additional information contained in the documents
described under the heading “Where You Can Find Additional Information” of this
prospectus before investing in shares of our common stock.
This
prospectus describes the general manner in which our common stock may be offered
by this prospectus. The selling stockholders may provide a prospectus supplement
when selling shares of our common stock. That prospectus supplement may include
a discussion of any special considerations that apply to those securities or
the
manner in which they are offered. The prospectus supplement provided by the
selling stockholders may also add, update or change information contained in
this prospectus. If there is any inconsistency between the information in this
prospectus and an accompanying prospectus supplement, you should rely on the
information in that prospectus supplement.
We
are a
biopharmaceutical company focusing on the development and commercialization
of
innovative therapeutic products to treat the unmet medical needs of patients
with debilitating conditions and life-threatening diseases. Our principal
programs are directed toward symptom management and supportive care and the
treatment of Human Immunodeficiency Virus (“HIV”) infection and cancer. We do
not have any FDA approved products and have not received any revenue from the
sale of any of our product candidates under development. The mailing address
of
our principal executive offices is 777 Old Saw Mill River Road, Tarrytown,
New
York 10591, and our telephone number is (914) 789-2800. References to
“Progenics,” the “Company,” “we,” “our” and “us” refers to Progenics
Pharmaceuticals, Inc. and its subsidiary.
Our
business and operations entail a variety of risks and uncertainties, including
those described below.
Our
product development programs are inherently risky.
We
are
subject to the risks of failure inherent in the development of product
candidates based on new technologies. Our MNTX product candidate, which is
designed to reverse certain side effects induced by opioids and to treat
post-operative bowel dysfunction and is being developed through a collaboration
with Wyeth, is based on a novel method of action that has not yet been proven
to
be safe or effective. No drug with MNTX’s method of action has ever received
marketing approval. Additionally, some of our HIV product candidates are
designed to be effective by blocking viral entry, and our GMK product candidate
is designed to be a therapeutic cancer vaccine. To our knowledge, no drug
designed to treat HIV infection by blocking viral entry (with one exception)
and
no cancer therapeutic vaccine has been approved for marketing in the U.S. Our
other research and development programs, and those conducted through our joint
venture with Cytogen, involve similarly novel approaches to human therapeutics.
Consequently, there is little precedent for the successful commercialization
of
products based on our technologies. There are a number of technological
challenges that we must overcome to complete most of our development efforts.
We
may not be able to develop successfully any of our products.
We
have granted to Wyeth the exclusive rights to develop and commercialize MNTX,
our lead product candidate, and our resulting dependence on Wyeth exposes us
to
significant risks.
In
December 2005, we entered into a license and co-development agreement
with
Wyeth.
Under this agreement, we granted to
Wyeth
the exclusive worldwide right to develop and commercialize MNTX, our lead
product candidate.
As a
result, we are dependent on Wyeth to perform and fund clinical testing, to
make
certain regulatory filings and to manufacture and market products containing
MNTX. Our collaboration with Wyeth may not be scientifically, clinically or
commercially successful.
Any
revenues from the sale of MNTX, if approved for sale by the FDA, will depend
almost entirely on the efforts of Wyeth. Wyeth has significant discretion
in
determining the efforts and resources it applies to sales of our products
and
may not be effective in marketing our products. In addition, Wyeth is a large,
diversified pharmaceutical company with global operations and its own corporate
agenda, which may not be consistent with our best interests. For example,
Wyeth
may change its strategic focus or pursue alternative technologies in a manner
that results in reduced revenues to us. In addition, we will receive milestone
payments from Wyeth only if MNTX achieves specified clinical, regulatory
and
commercialization milestones, and we will receive royalty payments from Wyeth
only if MNTX receives regulatory approval and is commercialized by Wyeth.
Many
of these milestone events will depend on the efforts of Wyeth. We may not
receive any milestone or royalty payments from Wyeth.
Wyeth
may
terminate the license and co-development agreement:
· |
for
any or no reason at any time after two years from the first commercial
sale of the first commercial product utilizing MNTX in the United
States
by providing us with at least 360
days prior written notice and complying with certain other
conditions;
|
· |
for
safety or efficacy reasons by providing us with at least 30 days
prior
written notice;
|
· |
upon
our material breach or non-compliance with our representations, warranties
and other obligations under the license and co-development agreement
if
the non-compliance is not cured; or
|
· |
upon
our bankruptcy or similar insolvency
event.
|
If
our
relationship with
Wyeth were to terminate, we would have to either enter into a license and
co-development agreement with another party or develop and commercialize MNTX
ourselves. We may not be able to enter into such an agreement with another
suitable company on acceptable terms or at all. To develop and commercialize
MNTX on our own, we would have to develop a sales and marketing organization
and
a distribution infrastructure, neither of which we currently have. Developing
these resources would be an expensive and lengthy process and would have a
material adverse effect on our revenues and profitability.
Moreover,
a termination of our relationship with
Wyeth could seriously compromise the development program for MNTX. For example,
we
could
experience significant delays in the development of MNTX and would
have to assume full funding and other responsibility for further development
and
eventual commercialization.
Any
of
these outcomes would result in delays in our ability to distribute MNTX and
would increase our expenses, which would have a material adverse effect on
our
business, results of operations and financial condition.
Our
collaboration with Wyeth is multi-faceted and involves a complex sharing of
control over decisions, responsibilities, costs and benefits. There are numerous
potential sources of disagreement between us and
Wyeth, including with respect to product development, marketing strategies,
manufacturing and supply issues and rights relating to intellectual property.
Wyeth
has
significantly greater financial and managerial resources than we do, which
it
could draw upon in the event of a dispute. A disagreement between Wyeth and
us
could lead to lengthy and expensive litigation or other dispute resolution
proceedings as well as to extensive financial and operational consequences
to
us, and have a material adverse effect on our business, results of operations
and financial condition.
If
testing does not yield successful results, our products will not be
approved.
We
will
need to obtain regulatory approval before we can market our product candidates.
To obtain marketing approval from regulatory authorities, we or our
collaborators must demonstrate a product’s safety and efficacy through extensive
preclinical and clinical testing. Numerous adverse events may arise during,
or
as a result of, the testing process, including the following:
· |
the
results of preclinical studies may be inconclusive, or they may not
be
indicative of results that will be obtained in human clinical trials;
|
· |
potential
products may not have the desired efficacy or may have undesirable
side
effects or other characteristics that preclude marketing approval
or limit
their commercial use if approved;
|
· |
after
reviewing test results, we or our collaborators may abandon projects,
which we previously believed to be promising; and
|
· |
we,
our collaborators or regulators may suspend or terminate clinical
trials
if we or they believe that the participating subjects or patients
are
being exposed to unacceptable health risks.
|
Clinical
testing is very expensive and can take many years. Results attained in early
human clinical trials may not be indicative of results that are obtained in
later clinical trials. In addition, many of our products, such as PRO 140 and
the PSMA product candidates, are at an early stage of development. The
successful commercialization of early stage products will require significant
further research, development, testing, approvals by regulators and additional
investment. Our products in the research or preclinical development stage may
not yield results that would permit or justify clinical testing. Our failure
to
adequately demonstrate the safety and efficacy of a product under development
would delay or prevent marketing approval of the product, which could adversely
affect our operating results and credibility.
A
setback in our clinical development programs could adversely affect
us.
We
have
several ongoing late-stage clinical trials. We have completed enrollment and
patient treatment in our two pivotal phase 3 clinical trials and in the
extension study for one of those trials of sub-cutaneous MNTX for the treatment
of opioid-induced constipation in patients with advanced medical illness.
Patient enrollment in the extension study of the second pivotal trial has been
completed and patient treatment is currently ongoing. We will need to
successfully complete and analyze the data from both of these trials, and their
extension studies, in order to obtain approval of the FDA to market MNTX. We
also have completed a phase 2 clinical trial of intravenous MNTX in patients
at
risk for post-operative bowel dysfunction and intend, working with our
collaborator Wyeth, to conduct additional clinical trials of oral MNTX in
chronic pain patients who experience opioid-induced constipation.
If
the
results of any of these ongoing trials are not satisfactory, or if we encounter
problems enrolling patients, or if clinical trial supply issues or other
difficulties arise, our entire MNTX development program could be adversely
affected, resulting in delays in commencing or completing clinical trials or
in
making our regulatory filing for marketing approval. The need to conduct
additional clinical trials or significant revisions to our clinical development
plan would lead to delays in filing for the regulatory approvals necessary
to
market MNTX. If the clinical trials indicate a serious problem with the safety
or efficacy of a MNTX product then Wyeth has the right under our license and
co-development agreement to terminate the agreement or to stop the development
or commercialization of the affected products. Since MNTX is our most clinically
advanced product, any setback of these types would have a material adverse
effect on our stock price and business.
We
also
have two ongoing pivotal phase 3 clinical trials for GMK. In May 2000, our
collaborating research cooperative group in one of these trials, ECOG,
recommended to clinical investigators participating in the trial that they
discontinue administering GMK, and as a result that trial did not complete
patient dosing as contemplated by the initial trial protocol. A second pivotal
phase 3 trial for GMK was initiated in May 2001 and full
enrollment of the 1,300 patients called for in the trial has been completed.
We
expect to assess the recurrence of cancer and overall survival of the study
patients over the next several years. If the results of either of the GMK trials
are not satisfactory, we may need to conduct additional clinical trials or
abandon our GMK program.
We
have
announced positive phase 1 clinical findings related to PRO 140, and we have
initiated an additional phase 1b clinical trial. We have also decided to ramp
down our development efforts on PRO 542, our other HIV product candidate, in
order to concentrate our resources on PRO 140. If the results of our phase
1b
study with PRO 140 or the preclinical and clinical studies involving the PSMA
vaccine and antibody candidates are not satisfactory, we would need to
reconfigure our clinical trial programs to conduct additional trials or abandon
the program involved.
We
have a history of operating losses, and we may never be
profitable.
We
have
incurred substantial losses since our inception. As of September 30, 2005,
we
had an accumulated deficit of approximately $156.0 million. We have derived
no
significant revenues from product sales or royalties. We do not expect to
achieve significant product sales or royalty revenue for a number of years,
if
ever, other than potential revenues from MNTX. We expect to incur additional
operating losses in the future, which could increase significantly as we expand
our clinical trial programs and other product development efforts.
Our
ability to achieve and sustain profitability is dependent in part on obtaining
regulatory approval to market our products and then commercializing, either
alone or with others, our products. We may not be able to develop and
commercialize products. Moreover, our operations may not be profitable even
if
any of our products under development are commercialized.
We
are likely to need additional financing, but our access to capital funding
is
uncertain.
As
of
September 30, 2005, we had cash, cash equivalents and marketable securities,
including non-current portion, totaling $128.0 million. In December 2005, we
received a $60 million upfront payment from Wyeth in connection with the signing
of the license and co-development agreement relating to MNTX. During the three
months and nine months ended September 30, 2005, we had a net loss of $10.7
million and $36.7 million, respectively, and we used cash in operating
activities of $33.4 million during the nine months ended September 30, 2005.
Under
our
agreement with Wyeth, Wyeth is responsible for all future development and
commercialization costs relating to MNTX starting January 1, 2006. As a result
we expect that our spending on MNTX in 2006 and beyond will drop significantly
from the amounts expended in 2005.
With
regard to our other product candidates, however, we expect that we will continue
to incur significant expenditures for their development and we do not have
committed external sources of funding for most of these projects. These
expenditures will be funded from our cash on hand, or we may seek additional
external funding for these expenditures, most likely through collaborative
agreements, or other license or sale transactions, with one or more
pharmaceutical companies, through the issuance and sale of securities or through
additional government grants or contracts. We cannot predict with any certainty
when we will need additional funds or how much we will need or if additional
funds will be available to us. Our need for future funding will depend on
numerous factors, many of which are outside our control.
Our
access to capital funding is uncertain. We may not be able to obtain additional
funding on acceptable terms, or at all. Our inability to raise additional
capital on terms reasonably acceptable to us would seriously jeopardize the
future success of our business.
If
we
raise funds by issuing and selling securities, it may be on terms that are
not
favorable to our existing stockholders. If we raise additional funds by selling
equity securities, our current stockholders will be diluted, and new investors
could have rights superior to our existing stockholders. If we raise funds
by
selling debt securities, we could be subject to restrictive covenants and
significant repayment obligations.
Our
clinical trials could take longer than we expect.
Although
for planning purposes we forecast the commencement and completion of clinical
trials, and have included or incorporated by reference many of those forecasts
in this prospectus and in other public disclosures, the actual timing of these
events can vary dramatically. For example, we have experienced delays in our
MNTX clinical development program in the past as a result of slower than
anticipated patient enrollment. These delays may recur. Delays can be caused
by,
among other things:
· |
deaths
or other adverse medical events involving patients or subjects in
our
clinical trials;
|
· |
regulatory
or patent issues;
|
· |
interim
or final results of ongoing clinical trials;
|
· |
failure
to enroll clinical sites as expected;
|
· |
scheduling
conflicts with participating clinicians and clinical institutions;
and
|
· |
manufacturing
problems.
|
In
addition, we may need to delay or suspend our clinical trials if we are unable
to obtain additional funding when needed. Also, our clinical programs involving
our joint venture with Cytogen Corporation ("Cytogen") could be delayed by
disagreements between Cytogen and us concerning funding development programs
or
other matters. For example, until June 2005, the joint venture had no approved
2005 budget or work plan because we and Cytogen had not yet reached agreement
with respect to a number of matters relating to the joint venture. In June
2005,
we and Cytogen approved a work plan and budget for 2005. We have not yet agreed
with Cytogen on a work plan and budget for 2006. Clinical trials involving
our
product candidates may not commence or be completed as forecasted.
Moreover,
we have limited experience in conducting clinical trials, and we rely on others
to conduct, supervise or monitor some or all aspects of some of our clinical
trials. In addition, certain clinical trials for our products may be conducted
by government-sponsored agencies, and consequently will be dependent on
governmental participation and funding. Under our agreement with Wyeth relating
to MNTX Wyeth has the responsibility to conduct some of the clinical trials
for
that product candidate, including all trials outside of the United States.
We
will have less control over the timing and other aspects of these clinical
trials than if we conducted them entirely on our own.
As
a
result of these and other factors, our clinical trials may not commence or
be
completed as we expect or may not be conducted successfully, in which event
investors’ confidence in our ability to develop products may be impaired and our
stock price may decline.
We
are subject to extensive regulation, which can be costly and time consuming
and
can subject us to unanticipated fines and delays.
We
and
our products are subject to comprehensive regulation by the FDA in the U.S.
and
by comparable authorities in other countries. These national agencies and other
federal, state and local entities regulate, among other things, the preclinical
and clinical testing, safety, approval, manufacture, labeling, marketing,
export, storage, record keeping, advertising and promotion of pharmaceutical
products. If we violate regulatory requirements at any stage, whether before
or
after marketing approval is obtained, we may be subject to forced removal of
a
product from the market, product seizure, civil and criminal penalties and
other
adverse consequences.
Our
products do not yet have, and may never obtain, the regulatory approvals needed
for marketing.
None
of
our products has been approved by applicable regulatory authorities for
marketing. The process of obtaining FDA and foreign regulatory approvals often
takes many years and can vary substantially based upon the type, complexity
and
novelty of the products involved. We have had only limited experience in filing
and pursuing applications and other submissions necessary to gain marketing
approvals. Our products under development may never obtain the marketing
approval from the FDA or any other regulatory authority necessary for
commercialization.
Even
if
our products receive regulatory approval:
· |
they
might not obtain labeling claims necessary to make the product
commercially viable (in general, labeling claims define the medical
conditions for which a drug product may be marketed, and are therefore
very important to the commercial success of a product);
|
· |
we
or our collaborators might be required to undertake post-marketing
trials
to verify the product’s efficacy or safety;
|
· |
we,
our collaborators or others might identify side effects after the
product
is on the market, or we or our collaborators might experience
manufacturing problems, either of which could result in subsequent
withdrawal of marketing approval, reformulation of the product, additional
preclinical testing or clinical trials, changes in labeling of the
product
or the need for additional marketing applications; and
|
· |
we
and our collaborators will be subject to ongoing FDA obligations
and
continuous regulatory review.
|
If
our
products fail to receive marketing approval or lose previously received
approvals, our financial results would be adversely affected.
Even
if our products obtain marketing approval, they might not be accepted in the
marketplace.
The
commercial success of our products will depend upon their acceptance by the
medical community and third party payors as clinically useful, cost effective
and safe. If healthcare providers believe that patients can be managed
adequately with alternative, currently available therapies, they may not
prescribe our products, especially if the alternative therapies are viewed
as
more effective, as having a better safety or tolerability profile, as being
more
convenient to the patient or healthcare providers or as being less expensive.
For pharmaceuticals administered in an institutional setting, the ability of
the
institution to be adequately reimbursed could also play a significant role
in
demand for our products. Even if our products obtain marketing approval, they
may not achieve market acceptance. If any of our products do not achieve market
acceptance, we will likely lose our entire investment in that
product.
Marketplace
acceptance will depend in part on competition in our industry, which is
intense.
The
extent to which any of our products achieves market acceptance will depend
on
competitive factors. Competition in our industry is intense, and it is
accentuated by the rapid pace of technological development. There are products
currently in the market that will compete with the products that we are
developing, including chemotherapy drugs for treating cancer and AIDS drugs.
As
described below, Adolor Corporation is developing a drug that would compete
with
MNTX. Many of our competitors have substantially greater research and
development capabilities and experience and greater manufacturing, marketing,
financial and managerial resources than we do. These competitors may develop
products that are superior to those we are developing and render our products
or
technologies non-competitive or obsolete. If our product candidates receive
marketing approval but cannot compete effectively in the marketplace, our
operating results and financial position would suffer.
One
or more competitors developing an opioid antagonist may reach the market ahead
of us and adversely affect the market potential for MNTX.
We
are
aware that Adolor Corporation, in collaboration with Glaxo Group Limited, or
Glaxo, a subsidiary of GlaxoSmithKline plc, is developing an opioid antagonist,
Entereg™ (alvimopan), for post-operative ileus, which has completed phase 3
clinical trials, and for opioid bowel dysfunction and chronic constipation,
which have completed phase 2 trials. Post-operative ileus is a condition similar
to post-operative bowel dysfunction, a condition for which we are developing
MNTX. Entereg is further along in the clinical development process than MNTX,
and Adolor Corporation has received an approvable letter from the U.S. Food
and
Drug Administration for Entereg regarding the treatment of post-operative ileus.
Additionally, it has been reported that a European specialty pharmaceutical
company is in clinical development of an oral formulation of methylnaltrexone
for use in opioid-induced constipation. If either of these products reaches
the
market before MNTX, it could achieve a significant competitive advantage
relative to our product. In any event, the considerable marketing and sales
capabilities of Glaxo may impair our ability to penetrate the market.
Under
the
terms of our collaboration with Wyeth with respect to MNTX, Wyeth will develop
the oral form of MNTX worldwide. We will lead the U.S. development of the
subcutaneous and intravenous forms of MNTX, while Wyeth will lead development
of
these parenteral products outside the U.S. Wyeth and we will pursue an
integrated strategy to optimize worldwide development, regulatory approval,
and
commercial launch of the three MNTX products, which may impact timelines for
the
development of MNTX previously disclosed by us. Decisions regarding the
timelines for development of the three MNTX products will be made by a Joint
Development Committee formed under the terms of the license and co-development
agreement, consisting of members from both Wyeth and Progenics.
Disputes
with Cytogen could delay or halt our PSMA programs.
Our
research and development programs relating to vaccine and antibody
immunotherapeutics based on PSMA are conducted through a joint venture between
Cytogen Corporation and us. The JV is a 50/50 joint venture, meaning that our
ownership rights in the programs, funding obligations and governance rights
are
equal. As a result, for the joint venture to operate efficiently, and for the
research and development programs to be adequately funded and staffed and
productive, we and Cytogen must be in agreement on strategic and operational
matters. There is a significant risk that, as a result of differing views and
priorities, there will be occasions when we do not agree on various
matters.
Cytogen’s
and our level of commitment to fund the PSMA joint venture is based upon annual
budgets and work plans that are developed and approved by the parties. We have
in the past experienced delays in reaching agreement with Cytogen regarding
annual budget issues and strategic and operational matters relating to the
joint
venture. For example, until June 2005, the joint venture had no approved 2005
budget or work plan because we and Cytogen had not yet reached agreement with
respect to a number of matters relating to the joint venture. In June 2005,
we
and Cytogen reached agreement on a work plan and budget for 2005.
We
have
not yet agreed with Cytogen on a work plan and budget for 2006. If we do not
reach an agreement regarding the budget and work plan for 2006 and future years,
we would likely experience delays in advancing the PSMA programs and may need
to
dissolve the joint venture and abandon the PSMA programs being conducted by
the
joint venture. We may not reach an agreement with Cytogen on these
matters.
If
we are unable to negotiate collaborative agreements, our cash burn rate could
increase and our rate of product development could
decrease.
Our
business strategy includes as an element entering into collaborations with
pharmaceutical and biotechnology companies to develop and commercialize our
products and technologies. We recently entered into such a collaboration with
Wyeth. However, we may not be successful in negotiating additional collaborative
arrangements. If we do not enter into new collaborative arrangements, we would
have to devote more of our resources to clinical product development and
product-launch activities, and our cash burn rate would increase or we would
need to take steps to reduce our rate of product development.
If
we do not remedy our failure to achieve milestones or satisfy conditions
regarding some of our product candidates, we may not maintain our rights under
our licenses relating to these product candidates.
We
are
required to make substantial cash payments, achieve specified milestones and
satisfy other conditions, including filing for and obtaining marketing approvals
and introducing products, to maintain rights under our intellectual property
licenses. We may not be able to maintain our rights under these
licenses.
Under
our
license agreements with Sloan Kettering Institute for Cancer Research relating
to GMK and with Columbia University relating to PRO 542, we are required, among
other things, to have filed for marketing approval for a drug by 2000 and to
have commenced commercialization of the drug by 2002 (for GMK) and to have
filed
for marketing approval by 2001 (for PRO 542). We have not achieved these and
other milestones and are unlikely to achieve them soon. We are in a similar
position with respect to our license agreement with Antigenics Inc. concerning
QS-21, a component of GMK. If we can establish that our failure to achieve
these
milestones resulted from technical issues beyond our control or delays in
clinical studies that could not have been reasonably avoided, we may be entitled
to a revision of these milestone dates. Although we believe that we satisfy
one
or more of these conditions, we may become involved in disputes with our
licensors as to our continued right to a license. In addition, at September
1,
2004 we became obligated under our license agreement with Columbia to pay
Columbia $225,000. We have accrued this amount but, pending the outcome of
discussions with Columbia regarding this payment and other matters relating
to
the license, we have not yet paid it.
If
we do
not comply with our obligations under our license agreements, the licensors
may
terminate them. Termination of any of our licenses could result in our losing
our rights to, and therefore being unable to commercialize, any related product.
We have had discussions with Sloan-Kettering and Columbia to reach agreement
on
the revision of applicable milestone dates. We may not, however, reach agreement
with these licensors in a manner favorable to us.
We
have limited manufacturing capabilities, which could adversely impact our
ability to commercialize products.
We
have
limited manufacturing capabilities, which may result in increased costs of
production or delay product development or commercialization. In order to
commercialize our product candidates successfully, we or our collaborators
must
be able to manufacture products in commercial quantities, in compliance with
regulatory requirements, at acceptable costs and in a timely manner. The
manufacture of our product candidates can be complex, difficult to accomplish
even in small quantities, difficult to scale-up for large-scale production
and
subject to delays, inefficiencies and low yields of quality products. The cost
of manufacturing some of our products may make them prohibitively expensive.
If
adequate supplies of any of our product candidates or related materials are
not
available to us on a timely basis or at all, our clinical trials could be
seriously delayed, since these materials are time-consuming to manufacture
and
cannot be readily obtained from third-party sources.
We
operate pilot-scale manufacturing facilities for the production of vaccines
and
recombinant proteins. We believe that, for these types of product candidates,
these facilities will be sufficient to meet our initial needs for clinical
trials. However, these facilities may be insufficient for late-stage clinical
trials for these types of product candidates, and would be insufficient for
commercial-scale manufacturing requirements. We may be required to expand
further our manufacturing staff and facilities, obtain new facilities or
contract with corporate collaborators or other third parties to assist with
production.
In
the
event that we decide to establish a commercial-scale manufacturing facility,
we
will require substantial additional funds and will be required to hire and
train
significant numbers of employees and comply with applicable regulations, which
are extensive. We may not be able to build a manufacturing facility that both
meets regulatory requirements and is sufficient for our clinical trials or
commercial-scale manufacturing.
We
have
entered into arrangements with third parties for the manufacture of some of
our
products. Our third-party sourcing strategy may not result in a cost-effective
means for manufacturing products. In employing third-party manufacturers, we
will not control many aspects of the manufacturing process, including compliance
by these third parties with the FDA’s current Good Manufacturing Practices and
other regulatory requirements. We may not be able to obtain adequate supplies
from third-party manufacturers in a timely fashion for development or
commercialization purposes, and commercial quantities of products may not be
available from contract manufacturers at acceptable costs.
We
are dependent on our patents and other intellectual property rights. The
validity, enforceability and commercial value of these rights are highly
uncertain.
Our
success is dependent in part on obtaining, maintaining and enforcing patent
and
other intellectual property rights. The patent position of biotechnology and
pharmaceutical firms is highly uncertain and involves many complex legal and
technical issues. There is no clear policy involving the breadth of claims
allowed, or the degree of protection afforded, under patents in this area.
Accordingly, the patent applications owned by or licensed to us may not result
in patents being issued. We are aware of other groups that have patent
applications or patents containing claims similar to or overlapping those in
our
patents and patent applications. We do not expect to know for several years
the
relative strength or scope of our patent position as compared to these other
groups. Furthermore, patents that we own or license may not enable us to
preclude competitors from commercializing drugs, and consequently may not
provide us with any meaningful competitive advantage.
We
own or
have licenses to several issued patents. However, the issuance of a patent
is
not conclusive as to its validity or enforceability. The validity or
enforceability of a patent after its issuance by the patent office can be
challenged in litigation. Our patents may be successfully challenged. Moreover,
we may incur substantial costs in litigation to uphold the validity of patents
or to prevent infringement. If the outcome of litigation is adverse to us,
third
parties may be able to use our patented invention without payment to us.
Moreover, third parties may avoid our patents through design
innovation.
Most
of
our product candidate, including MNTX, PRO 140, GMK and our PSMA program
products, incorporate to some degree intellectual property licensed from third
parties. We can lose the right to patents and other intellectual property
licensed to us if the related license agreement is terminated due to a breach
by
us or otherwise. Our ability, and that of our collaboration partners, to
commercialize products incorporating licensed intellectual property would be
impaired if the related license agreements were terminated.
Generally,
we have the right to defend and enforce patents licensed by us, either in the
first instance or if the licensor chooses not to do so. In addition, our license
agreement with the University of Chicago regarding MNTX gives us the right
to
prosecute and maintain the licensed patents. We bear the cost of engaging in
some or all of these activities with respect to our license agreements with
Sloan-Kettering for GMK, Columbia for PRO 542 and the University of Chicago
for
MNTX. With
most
of our other license agreements, the licensor bears the cost of engaging in
all
of these activities, although we may share in those costs under specified
circumstances. Historically, our costs of defending patent rights, both our
own
and those we license, have not been material.
We
also
rely on unpatented technology, trade secrets and confidential information.
Third
parties may independently develop substantially equivalent information and
techniques or otherwise gain access to our technology or disclose our
technology, and we may be unable to effectively protect our rights in unpatented
technology, trade secrets and confidential information. We require each of
our
employees, consultants and advisors to execute a confidentiality agreement
at
the commencement of an employment or consulting relationship with us. However,
these agreements may not provide effective protection in the event of
unauthorized use or disclosure of confidential information.
If
we infringe third-party patent or other intellectual property rights, we may
need to alter or terminate a product development program.
There
may
be patent or other intellectual property rights belonging to others that require
us to alter our products, pay licensing fees or cease certain activities. If
our
products infringe patent or other intellectual property rights of others, the
owners of those rights could bring legal actions against us claiming damages
and
seeking to enjoin manufacturing and marketing of the affected products. If
these
legal actions are successful, in addition to any potential liability for
damages, we could be required to obtain a license in order to continue to
manufacture or market the affected products. We may not prevail in any action
brought against us, and any license required under any rights that we infringe
may not be available on acceptable terms or at all. We are aware of intellectual
property rights held by third parties that relate to products or technologies
we
are developing. For example, we are aware of other groups investigating
methylnaltrexone and other peripheral opioid antagonists, PSMA or related
compounds and CCR5 monoclonal antibodies and of patents held, and patent
applications filed, by these groups in those areas. While the validity of these
issued patents, patentability of these pending patent applications and
applicability of any of them to our programs are uncertain, if asserted against
us, any related patent or other intellectual property rights could adversely
affect our ability to commercialize our products.
The
research, development and commercialization of a biopharmaceutical often involve
alternative development and optimization routes, which are presented at various
stages in the development process. The preferred routes cannot be predicted
at
the outset of a research and development program because they will depend on
subsequent discoveries and test results. There are numerous third-party patents
in our field, and we may need to obtain a license to a patent in order to pursue
the preferred development route of one or more of our products. The need to
obtain a license would decrease the ultimate profitability of the applicable
product. If we cannot negotiate a license, we might have to pursue a less
desirable development route or terminate the program altogether.
We
are dependent upon third parties for a variety of functions. These arrangements
may not provide us with the benefits we expect.
We
rely
in part on third parties to perform a variety of functions. We are party to
numerous agreements which place substantial responsibility on clinical research
organizations, consultants and other service providers for the development
of
our products. We also rely on medical and academic institutions to perform
aspects of our clinical trials of product candidates. In addition, an element
of
our research and development strategy is to in-license technology and product
candidates from academic and government institutions in order to minimize
investments in early research. Furthermore, we recently entered into an
agreement under which we will depend on Wyeth for the commercialization and
development of MNTX, our lead product candidate. We may not be able to maintain
any of these relationships or establish new ones on beneficial terms.
Furthermore, we may not be able to enter new arrangements without undue delays
or expenditures, and these arrangements may not allow us to compete
successfully.
We
lack sales and marketing experience, which will make us dependent on third
parties for their expertise in this area.
We
have
no experience in sales, marketing or distribution. If we receive marketing
approval, we expect to market and sell our products principally through
distribution, co-marketing, co-promotion or licensing arrangements with third
parties. We may also consider contracting with a third party professional
pharmaceutical detailing and sales organization to perform the marketing
function for our products. Under our license and co-development agreement with
Wyeth, Wyeth is responsible for commercializing MNTX. To the extent that we
enter into distribution, co-marketing, co-promotion, detailing or licensing
arrangements for the marketing and sale of our other products, any revenues
we
receive will depend primarily on the efforts of third parties. We will not
control the amount and timing of marketing resources these third parties devote
to our products. In addition, if we market products directly, significant
additional expenditures and management resources would be required to develop
an
internal sales force. We may not be able to establish a successful sales force
should we choose to do so.
If
we lose key management and scientific personnel on whom we depend, our business
could suffer.
We
are
dependent upon our key management and scientific personnel. In particular,
the
loss of Dr. Paul J. Maddon, our Chief Executive Officer and Chief Science
Officer, could cause our management and operations to suffer. We have an
employment agreement with Dr. Maddon, the initial term of which ran through
September 30, 2005, subject to an automatic renewal for an additional period
of
two years unless either party provides ninety days prior notice of non-renewal.
See “Item 11. Executive Compensation - Employment Agreements” in our Annual
Report on Form 10-K for the year ended December 31, 2004. Neither we nor Dr.
Maddon gave notice of non-renewal. We are currently in discussions with Dr.
Maddon regarding the renewal of his employment agreement and expect that the
agreement will be renewed. Employment agreements do not, however, assure the
continued employment of an employee. We maintain key-man life insurance on
Dr.
Maddon in the amount of $2.5 million.
In
October 2004, our Board of Directors elected Paul F. Jacobson and Kurt W. Briner
as Co-chairmen of the Board in substitution of Dr. Paul J. Maddon, our Chief
Executive Officer, Chief Science Officer and a director. Dr. Maddon’s employment
agreement contains provisions relating to the Chairmanship position. In
connection with the renewal of Dr. Maddon’s employment agreement, we intend to
clarify that the change in the Chairman position is not inconsistent with Dr.
Maddon’s employment agreement.
Competition
for qualified employees among companies in the biopharmaceutical industry is
intense. Our future success depends upon our ability to attract, retain and
motivate highly skilled employees. In order to commercialize our products
successfully, we may be required to expand substantially our personnel,
particularly in the areas of manufacturing, clinical trials management,
regulatory affairs, business development and marketing. We may not be successful
in hiring or retaining qualified personnel.
If
we are unable to obtain sufficient quantities of the raw and bulk materials
needed to make our products, our product development and commercialization
could
be slowed or stopped.
We
currently obtain supplies of critical raw materials used in production of MNTX,
GMK and other of our product candidates from single sources. In particular,
we
rely on single-source third-party manufacturers for the supply of both bulk
and
finished form MNTX. We have a supply agreement with Mallinckrodt Inc., our
current supplier of bulk-form MNTX, which has an initial term that expires
on
January 1, 2008. In accordance with our collaboration with Wyeth, we will
transfer to Wyeth, at a mutually agreeable time, the responsibility for
manufacturing MNTX for clinical and commercial use, including our supply
agreements with third parties. We do not have long-term contracts with any
of
our other suppliers. In addition, commercialization of GMK requires an adjuvant,
QS-21, available only from Antigenics Inc. Our existing arrangements may not
result in the supply of sufficient quantities of our product candidates needed
to accomplish our clinical development programs, and we may not have the right
or capability to manufacture sufficient quantities of these products to meet
our
needs if our suppliers are unable or unwilling to do so. Any delay or disruption
in the availability of raw materials would slow or stop product development
and
commercialization of the relevant product.
A
substantial portion of our funding comes from federal government grants and
research contracts. We cannot rely on these grants or contracts as a continuing
source of funds.
A
substantial portion of our revenues to date has been derived from federal
government grants and research contracts. In September 2005, we were awarded
a
$10.1 million grant from the NIH to partially fund our PRO 140 program. Also,
in
2004 we were awarded, in the aggregate, approximately $9.2 million in NIH grants
and research contracts in addition to previous years’ awards. We cannot rely on
grants or additional contracts as a continuing source of funds. Moreover, funds
available under these grants and contracts must be applied by us toward the
research and development programs specified by the government rather than for
all our programs generally. For example, the $28.6 million contract awarded
to
us by the NIH in September 2003 must be used by us in furtherance of our efforts
to develop an HIV vaccine. The government’s obligation to make payments under
these grants and contracts is subject to appropriation by the U.S. Congress
for
funding in each year. Moreover, it is possible that Congress or the government
agencies that administer these government research programs will decide to
scale
back these programs or terminate them due to their own budgetary constraints.
Additionally, these grants and research contracts are subject to adjustment
based upon the results of periodic audits performed on behalf of the granting
authority. Consequently, the government may not award grants or research
contracts to us in the future, and any amounts that we derive from existing
grants or contracts may be less than those received to date.
If
health care reform measures are enacted, our operating results and our ability
to commercialize products could be adversely affected.
In
recent
years, there have been numerous proposals to change the health care system
in
the U.S. and in foreign jurisdictions. Some of these proposals have included
measures that would limit or eliminate payments for medical procedures and
treatments or subject the pricing of pharmaceuticals to government control.
In
some foreign countries, particularly countries of the European Union, the
pricing of prescription pharmaceuticals is subject to governmental control.
In
addition, as a result of the trend towards managed health care in the U.S.,
as
well as legislative proposals to reduce government insurance programs,
third-party payors are increasingly attempting to contain health care costs
by
limiting both coverage and the level of reimbursement of new drug products.
Consequently, significant uncertainty exists as to the reimbursement status
of
newly approved health care products.
If
we or
any of our collaborators succeed in bringing one or more of our products to
market, third-party payors may establish and maintain price levels insufficient
for us to realize an appropriate return on our investment in product
development. Significant changes in the health care system in the U.S. or
elsewhere, including changes resulting from adverse trends in third-party
reimbursement programs, could have a material adverse effect on our operating
results and our ability to raise capital and commercialize
products.
We
are exposed to product liability claims, and in the future we may not be able
to
obtain insurance against these claims at a reasonable cost or at
all.
Our
business exposes us to product liability risks, which are inherent in the
testing, manufacturing, marketing and sale of pharmaceutical products. We may
not be able to avoid product liability exposure. If a product liability claim
is
successfully brought against us, our financial position may be adversely
affected.
Product
liability insurance for the biopharmaceutical industry is generally expensive,
when available at all. We have obtained product liability insurance in the
amount of $5.0 million per occurrence, subject to a deductible and a $5.0
million annual aggregate limitation. In addition, where local statutory
requirements exceed the limits of our existing insurance or where local policies
of insurance are required, we maintain additional clinical trial liability
insurance to meet these requirements. Our present insurance coverage may not
be
adequate to cover claims brought against us. In addition, some of our license
and other agreements require us to obtain product liability insurance. Adequate
insurance coverage may not be available to us at a reasonable cost in the
future.
We
handle hazardous materials and must comply with environmental laws and
regulations, which can be expensive and restrict how we do business. If we
are
involved in a hazardous waste spill or other accident, we could be liable for
damages, penalties or other forms of censure.
Our
research and development work and manufacturing processes involve the use of
hazardous, controlled and radioactive materials. We are subject to federal,
state and local laws and regulations governing the use, manufacture, storage,
handling and disposal of these materials. Despite procedures that we implement
for handling and disposing of these materials, we cannot eliminate the risk
of
accidental contamination or injury. In the event of a hazardous waste spill
or
other accident, we could be liable for damages, penalties or other forms of
censure. In addition, we may be required to incur significant costs to comply
with environmental laws and regulations in the future.
Our
stock price has a history of volatility. You should consider an investment
in
our stock as risky and invest only if you can withstand a significant
loss.
Our
stock
price has a history of significant volatility. Between January 1, 2002 and
September 30, 2005, our stock price has ranged from $3.82 to $25.07 per share.
At times, our stock price has been volatile even in the absence of significant
news or developments relating to us. Moreover, the stocks of biotechnology
companies and the stock market generally have been subject to dramatic price
swings in recent years. Factors that may have a significant impact on the market
price of our common stock include:
· |
the
results of clinical trials and preclinical studies involving our
products
or those of our competitors;
|
· |
changes
in the status of any of our drug development programs, including
delays in
clinical trials or program terminations;
|
· |
developments
regarding our efforts to achieve marketing approval for our products;
|
· |
developments
in our relationship with Wyeth regarding the development and
commercialization of MNTX;
|
· |
announcements
of technological innovations or new commercial products by us, our
collaborators or our competitors;
|
· |
developments
in our relationships with other collaborative partners;
|
· |
developments
in patent or other proprietary rights;
|
· |
governmental
regulation;
|
· |
changes
in reimbursement policies or health care legislation;
|
· |
public
concern as to the safety and efficacy of products developed by us,
our
collaborators or our competitors;
|
· |
our
ability to fund on-going operations;
|
· |
fluctuations
in our operating results; and
|
· |
general
market conditions.
|
Our
principal stockholders are able to exert significant influence over matters
submitted to stockholders for approval.
At
September 30, 2005, Dr. Maddon and stockholders affiliated with Tudor Investment
Corporation together beneficially own or control approximately 19% of our
outstanding shares of common stock. These persons, should they choose to act
together, could exert significant influence in determining the outcome of
corporate actions requiring stockholder approval and otherwise control our
business. This control could have the effect of delaying or preventing a change
in control of us and, consequently, could adversely affect the market price
of
our common stock.
Anti-takeover
provisions may make the removal of our Board of Directors or management more
difficult and discourage hostile bids for control of our company that may be
beneficial to our stockholders.
Our
Board
of Directors is authorized, without further stockholder action, to issue from
time to time shares of preferred stock in one or more designated series or
classes. The issuance of preferred stock, as well as provisions in certain
of
our stock options that provide for acceleration of exercisability upon a change
of control, and Section 203 and other provisions of the Delaware General
Corporation Law could:
· |
make
the takeover of Progenics or the removal of our Board of Directors
or
management more difficult;
|
· |
discourage
hostile bids for control of Progenics in which stockholders may receive
a
premium for their shares of common stock; and
|
· |
otherwise
dilute the rights of holders of our common stock and depress the
market
price of our common stock.
|
If
there are substantial sales of our common stock, the market price of our common
stock could decline.
Sales
of
substantial numbers of shares of common stock could cause a decline in the
market price of our stock. We require substantial external funding to finance
our research and development programs and may seek such funding through the
issuance and sale of our common stock. Sales of our common stock pursuant to
this registration statement could cause the market price or our stock to
decline. In addition, some of our other stockholders are entitled to require
us
to register their shares of common stock for offer or sale to the public. Also,
we have filed Form S-8 registration statements registering shares issuable
pursuant to our equity compensation plans. Any sales by existing stockholders
or
holders of options may have an adverse effect on our ability to raise capital
and may adversely affect the market price of our common stock.
Certain
statements in this prospectus, any prospectus supplement and the documents
we
have filed with the Securities and Exchange Commission that are incorporated
by
reference into this prospectus and any prospectus supplement constitute
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995. Included in these forward-looking statements
are
statements regarding our expectations for beginning or completing clinical
trials, submitting to regulatory authorities applications for marketing
approvals for our product candidates, raising additional capital and reducing
our operating costs if we cannot raise additional funds. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
which may cause our actual results, performance or achievements, or industry
results, to be materially different from any expected future results,
performance or achievements expressed or implied by such forward-looking
statements. These factors include, among others, the risks associated with
our
dependence on Wyeth to fund clinical testing, to make certain regulatory filings
and to manufacture and market products containing MNTX, the uncertainties
associated with product development, the risk that clinical trials will not
commence, proceed or be completed as planned, the risk that our products will
not receive marketing approval from regulators, the risks and uncertainties
associated with the dependence upon the actions of our corporate, academic
and
other collaborators and of government regulatory agencies, the risk that our
licenses to intellectual property may be terminated because of our failure
to
have satisfied performance milestones, the risk that products that appear
promising in early clinical trials are later found not to work effectively
or
are not safe, the risk that we may not be able to manufacture commercial
quantities of our products, the risk that our products, if approved for
marketing, do not gain market acceptance sufficient to justify development
and
commercialization costs, the risk that we will not be able to obtain funding
necessary to conduct our operations, the uncertainty of future profitability
and
other factors set forth more fully in this prospectus, any prospectus supplement
and the documents incorporated by reference herein, including those factors
described under the caption “Risk Factors,” to which investors are referred for
further information.
We
do not
have a policy of updating or revising forward-looking statements, and we assume
no obligation to update any forward-looking statements contained or incorporated
by reference in this prospectus and any accompanying prospectus supplement
as a
result of new information or future events or developments. Thus, you should
not
assume that our silence over time means that actual events are bearing out
as
expressed or implied in such forward-looking statements.
We
will
not receive any proceeds from the sale by the selling stockholders of the shares
of common stock they may offer through this prospectus.
We
are
registering for resale 186,000 shares of our common stock held by the selling
stockholders named below pursuant to this prospectus and any applicable
prospectus supplement. The shares subject to resale hereunder were
issued in connection with our acquisition of contract rights previously held
by
Susanne Glink, Mark Goldberg and the Claudia Otee Trust (collectively, the
“selling stockholders”). This transaction was completed on December 22, 2005.
The rights that we acquired provided for UR Labs, Inc. (“UR Labs”) to make
payments to the selling stockholders in respect of payments received by UR
Labs
as a result of its licensing to us intellectual property relating to MNTX.
Our
acquisition of these rights effectively extinguished UR Labs’ payment
obligations to the selling stockholders. As part of this acquisition, we agreed
to register for resale by the selling stockholders the 186,000 shares of our
common stock issued to them. We also agreed to provide indemnification rights
to
the selling stockholders.
The
selling stockholders may sell all, a portion or none of the shares covered
by
this prospectus at any time up to December
22, 2007. We are not obligated to maintain in effect after that date the
registration statement of which this prospectus forms a part. The selling
stockholders may also sell, transfer or otherwise dispose of some or all of
their shares (including shares not covered by this prospectus) in transactions
exempt from the registration requirements of the Securities Act of 1933 (the
“Securities Act”). We do not know when or in what amounts the selling
stockholders may offer shares under this prospectus or otherwise. As a result,
we cannot estimate with certainty the number of shares of our common stock
that
will be owned by each selling stockholder after the completion of any offering
contemplated by this prospectus.
|
Shares
Beneficially Owned Prior to Offering
|
|
Shares
to be Beneficially Owned After Offering
|
Name
|
Total
Number of Shares Beneficially Owned(1)
|
Percentage
Ownership(2)
|
Total
Number of Shares Offered for Resale(3)
|
Total
Number of Shares Beneficially Owned(4)
|
Percentage
Ownership(2)
|
Susanne
Glink
|
83,342
|
*
|
82,342
|
1,000
|
*
|
Mark
Goldberg
|
51,829
|
*
|
51,829
|
0
|
0%
|
The
Claudia Otee Trust
|
51,829
|
*
|
51,829
|
0
|
0%
|
Total
|
187,000
|
*
|
186,000
|
1,000
|
*
|
*
less
than one percent
(1)
This
column lists all shares of our common stock beneficially owned by the selling
stockholders, whether or not registered hereunder. We cannot assure you that
the
selling stockholders will sell any or all of such shares of common
stock.
(2)
The
total number of shares outstanding used in calculating the percentage owned
is
based on 25,233,132 shares of our common stock outstanding as of January 5,
2006.
(3)
Only
the shares of common stock registered hereunder, as shown in this column for
each selling stockholder, may be offered and resold by the selling stockholder
pursuant to this prospectus.
(4)
This
column lists all shares of our common stock beneficially owned by the selling
stockholders, whether or not registered hereunder, assuming all shares of common
stock registered hereunder are sold by the selling stockholders.
The
selling stockholders may sell the shares being offered from time to time in
one
or more transactions:
· |
on
The Nasdaq National Market;
|
· |
in
the over−the−counter market;
|
· |
in
privately negotiated transactions;
|
· |
through
broker−dealers, who may act as agents or
principals;
|
· |
through
one or more underwriters on a firm commitment or best efforts
basis;
|
· |
through
the writing of options on shares, whether the options are listed
on an
options exchange or otherwise; or
|
· |
a
combination of such methods of
sale.
|
The
shares may be sold at fixed prices that may be changed, at market prices
prevailing at the time of sale, at prices related to such market prices or
at
negotiated prices. Such transactions may or may not involve brokers or dealers.
Any brokers or dealers participating in a transaction may receive compensation
in the form of discounts, commissions or concessions from the selling
stockholders or the purchasers of shares for whom such brokers or dealers act
as
agent or to whom they sell as principal, or both (which compensation as to
a
particular broker or dealer might be in excess of customary
commissions).
The
shares can only be sold through registered or licensed brokers or dealers if
required under applicable state securities laws. In addition, in certain states
the shares may not be sold unless they have been registered or qualified for
sale in the applicable state or an exemption from the registration or
qualification requirement is available and is complied with.
The
selling stockholders and any brokers, dealers or agents that act in connection
with the sale of shares might be deemed to be “underwriters” within the meaning
of Section 2(11) of the Securities Act, and any commissions received by any
such
brokers, dealers or agents, and any profits realized on the resale of shares
sold by them while acting as principals, might be deemed to be underwriting
discounts and commissions under the Securities Act.
The
selling stockholders will be subject to the prospectus delivery requirements
of
the Securities Act with respect to sales of shares through this prospectus.
We
intend to inform the selling stockholders that the anti-manipulation provisions
of Regulation M promulgated under the Securities Exchange Act of 1934 may apply
to their sales in the market.
The
selling stockholders also may resell all or a portion of their shares in open
market transactions in reliance on Rule 144 under the Securities Act, provided
they conform to the requirements of Rule 144, including a one-year holding
period.
We
will
bear all costs, expenses and fees in connection with the registration of the
shares. The selling stockholders will bear all commissions and discounts, if
any, attributable to the sales of the shares. The selling stockholders may
agree
to indemnify certain persons, including broker−dealers and agents, against
certain liabilities in connection with the offering of the shares, including
liabilities arising under the Securities Act.
The
validity of the common stock being offered hereby will be passed upon for us
by
Dewey Ballantine LLP, New York, New York.
The
financial statements and management’s assessment of the effectiveness of
internal control over financial reporting (which is included in Management’s
Report on Internal Control over Financial Reporting) incorporated in this
Prospectus by reference to the Annual Report on Form 10-K for the year ended
December 31, 2004 have been so incorporated in reliance on the report of
PricewaterhouseCoopers LLP, an independent registered public accounting firm,
given on the authority of said firm as experts in auditing and
accounting.
WHERE
YOU CAN FIND ADDITIONAL INFORMATION
We
are
subject to the reporting requirements of the Securities Exchange Act of 1934,
and in accordance with its requirements file annual and quarterly reports,
proxy
statements and other information with the Securities and Exchange Commission.
These reports, proxy statements and other information may be inspected, and
copies of these materials may be obtained upon payment of the prescribed fees,
at the SEC’s Public Reference Room, 100 F Street, N.E., Washington D.C. 20549.
Please call the SEC at 1-800-SEC-0330 for further information regarding the
Public Reference Room. In addition, we are required to file electronic versions
of these materials with the SEC through the SEC’s Electronic Data Gathering,
Analysis and Retrieval (EDGAR) system. The SEC maintains an internet site at
http://www.sec.gov that contains reports, proxy and information statements
and
other information regarding registrants that file electronically with the SEC.
We
have
filed with the SEC a registration statement on Form S-3 under the Securities
Act
with respect to the common stock offered by this prospectus and any accompanying
prospectus supplement. This prospectus and, if applicable, any accompanying
prospectus supplement do not contain all of the information set forth in the
registration statement and the exhibits and the schedules to the registration
statement. For further information with respect to us and our common stock,
you
should read the registration statement, including its exhibits and schedules.
Statements contained in this prospectus and any accompanying prospectus
supplement, including documents that we have incorporated by reference, as
to
the contents of any contract or other document referred to are not necessarily
complete, and, with respect to any contract or other document filed as an
exhibit to the registration statement, each such statement is qualified in
all
respects by reference to the corresponding exhibit. Copies of the registration
statement and its exhibits are on file at the offices of the SEC and may be
obtained upon payment of the prescribed fee or may be examined without charge
at
the SEC’s Public Reference Room, at the address listed above, or via the EDGAR
database.
The
SEC
allows us to incorporate by reference information in this prospectus and any
accompanying prospectus supplement. This means that we can disclose important
information to you by referring you to another document filed separately with
the SEC. The information incorporated by reference is considered to be part
of
this prospectus and, if applicable, the accompanying prospectus supplement,
except for any information superseded by information contained directly in
this
prospectus and any accompanying prospectus supplement or in any subsequently
filed incorporated document. This prospectus and any accompanying prospectus
supplement incorporate by reference the documents set forth below that we have
previously filed with the SEC (other than information in such documents that
is
deemed to be furnished and not filed). These documents contain important
information about us and our financial condition.
· |
Our
Annual Report on Form 10-K for the year ended December 31, 2004,
File No.
000-23143;
|
· |
Our
Quarterly Report on Form 10-Q for the three months ended March 31,
2005,
File No. 000-23143;
|
· |
Our
Quarterly Report on Form 10-Q for the six months ended June 30, 2005,
File
No. 000-23143;
|
· |
Our
Quarterly Report on Form 10-Q for the nine months ended September
30,
2005, File No. 000-23143;
|
· |
Our
Current Reports on Form 8-K filed on:
|
—
January
14, 2005, File No. 0-23143;
—
January
14, 2005, File No. 0-23143;
—
February 25, 2005, File No. 0-23143;
—
March
2, 2005, File No. 0-23143;
—
March
10, 2005, File No. 0-23143;
—
April
5, 2005, File No. 0-23143;
—
May
13,
2005, File No. 0-23143;
—
June
8,
2005, File No. 0-23143;
—
June
13, 2005, File No. 0-23143;
—
June
29, 2005, File No. 0-23143;
—
September 15, 2005, File No. 0-23143;
— |
December
28, 2005, File No.0-23143
|
— |
January
9, 2006, File No. 0-23143; and
|
· |
The
description of our common stock contained in our Registration Statement
on
Form 8-A, dated September 29, 1997, File No. 0-23143, including any
amendments or reports filed for the purpose of updating such description.
|
All
documents filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the
Securities Exchange Act of 1934:
· |
subsequent
to the date of this prospectus and prior to the completion of this
offering of our common stock; and
|
· |
after
the date of the initial registration statement and prior to the
effectiveness of the registration
statement
|
will
be
deemed to be incorporated by reference in this prospectus and any accompanying
prospectus supplement and to be a part hereof from the date of filing of such
documents.
Any
statement contained in a document incorporated or deemed to be incorporated
by
reference in this prospectus or any accompanying prospectus supplement shall
be
deemed to be modified or superseded for purposes of this prospectus and the
accompanying prospectus supplement to the extent that a statement contained
in
this prospectus or the accompanying prospectus supplement, or in any other
subsequently filed document that is also incorporated or deemed to be
incorporated by reference in this prospectus and the accompanying prospectus
supplement, modifies or supersedes the earlier statement. Any statement so
modified or superseded shall not be deemed, except as so modified or superseded,
to constitute a part of this prospectus or the accompanying prospectus
supplement.
Documents
incorporated by reference are available from us without charge, excluding all
exhibits unless specifically incorporated by reference as an exhibit to this
prospectus and the accompanying prospectus supplement. Prospective investors
may
obtain documents incorporated by reference in this prospectus and the
accompanying prospectus supplement by requesting them in writing or by telephone
from us at our executive offices at 777 Old Saw Mill River Road, Tarrytown,
New
York 10591, telephone number (914) 789-2800, Attention: Richard W. Krawiec,
Ph.D., Vice President, Investor Relations and Corporate
Communications.
PART
II
INFORMATION
NOT REQUIRED IN PROSPECTUS
Item
14. Other Expenses of Issuance and Distribution.
Except
for the SEC registration fee and the NASD filing fee, all expenses are
estimated. All such expenses will be paid by the Registrant.
Registration
Fee—Securities
and Exchange Commission
|
|
$
|
532
|
|
Accountants’
fees and expenses
|
|
|
25,000
|
|
Legal
fees and expenses
|
|
|
25,000
|
|
Printing
and engraving expenses
|
|
|
1,000
|
|
Transfer
agent and registrar fees
|
|
|
3,500
|
|
Miscellaneous
|
|
|
968
|
|
Total
|
|
$
|
56,000
|
|
Item
15. Indemnification of Directors And Officers
Section
145(a) of the General Corporation Law of the State of Delaware (the “DGCL”)
provides that a Delaware corporation may indemnify any person who was or is
a
party or is threatened to be made a party to any threatened, pending or
completed action, suit or proceeding, whether civil, criminal, administrative
or
investigative (other than an action by or in the right of the corporation)
by
reason of the fact that he is or was a director, officer, employee or agent
of
the corporation or is or was serving at the request of the corporation as a
director, officer, employee or agent of another corporation or enterprise,
against expenses, judgments, fines and amounts paid in settlement actually
and
reasonably incurred by him in connection with such action, suit or proceeding
if
he acted in good faith and in a manner he reasonably believed to be in or not
opposed to the best interests of the corporation, and, with respect to any
criminal action or proceeding, he had no cause to believe his conduct was
unlawful.
Section
145(b) of the DGCL provides that a Delaware corporation may indemnify any person
who was or is a party or is threatened to be made a party to any threatened,
pending or completed action or suit by or in the right of the corporation to
procure a judgment in its favor by reason of the fact that such person acted
in
any of the capacities set forth above, against expenses actually and reasonably
incurred by him in connection with the defense or settlement of such action
or
suit if he acted under similar standards, except that no indemnification may
be
made in respect of any claim, issue or matter as to which such person shall
have
been adjudged to be liable to the corporation unless and only to the extent
that
the court in which such action or suit was brought shall determine that despite
the adjudication of liability, such person is fairly and reasonably entitled
to
be indemnified for such expenses which the court shall deem proper.
Section
145 of the DGCL further provides that to the extent a director or officer of
a
corporation has been successful in the defense of any action, suit or proceeding
referred to in subsections (a) and (b) or in the defense of any claim, issue,
or
matter therein, he shall be indemnified against expenses (including attorneys’
fees) actually and reasonably incurred by him in connection therewith; that
indemnification provided for by Section 145 shall not be deemed exclusive of
any
other rights to which the indemnified party may be entitled; and that the
corporation may purchase and maintain insurance on behalf of a director or
officer of the corporation against any liability asserted against him or
incurred by him in any such capacity or arising out of his status as such
whether or not the corporation would have the power to indemnify him against
such liabilities under such Section 145.
Section
102(b)(7) of the DGCL provides that a corporation in its original certificate
of
incorporation or an amendment thereto validly approved by stockholders may
eliminate or limit personal liability of members of its board of directors
or
governing body for breach of a director’s fiduciary duty. However, no such
provision may eliminate or limit the liability of a director for breaching
his
duty of loyalty, failing to act in good faith, engaging in intentional
misconduct or knowingly violating a law, paying a dividend or approving a stock
repurchase which was illegal, or obtaining an improper personal benefit. A
provision of this type has no effect on the availability of equitable remedies,
such as injunction or rescission, for breach of fiduciary duty. The Registrant’s
Restated Certificate of Incorporation contains such a provision.
The
Registrant’s Certificate of Incorporation and By-Laws provide that the
Registrant shall indemnify officers, directors, employees and agents of the
Registrant, to the full extent permitted by and in the manner permissible under
the laws of the State of Delaware. In addition, the By-Laws permit the Board
of
Directors to authorize the Registrant to purchase and maintain insurance against
any liability asserted against any director, officer, employee or agent of
the
Registrant arising out of his capacity as such.
The
Registrant has entered into Indemnification Agreements with each of its officers
and directors, pursuant to which the Registrant has agreed to indemnify and
advance expenses to such officers and directors to the fullest extent permitted
by applicable law.
The
Registrant has obtained an insurance policy providing coverage for certain
liabilities of its officers and directors.
Item
16. Exhibits.
Exhibit
Number
|
Description
of Exhibit
|
|
|
5.1
|
Opinion
of Dewey Ballantine LLP
|
23.1
|
Consent
of PricewaterhouseCoopers LLP
|
23.2
|
Consent
of Dewey Ballantine LLP (included in exhibit 5.1)
|
24.1
|
Power
of Attorney (included on the signature pages to this Registration
Statement).
|
______________
Item
17. Undertakings.
The
undersigned registrant does hereby undertake:
(1) |
to
file, during any period in which offers or sales are being made,
a
post-effective amendment to this registration statement:
|
(i) |
to
include any prospectus required by Section 10(a)(3) of the Securities
Act of 1933;
|
(ii) |
to
reflect in the prospectus any facts or events arising after the effective
date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent
a
fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease
in
volume of securities offered (if the total dollar value of securities
offered would not exceed that which has been registered) and any
deviation
from the low or high end of the estimated maximum offering range
may be
reflected in the form of prospectus filed with the Commission pursuant
to
Rule 424(b) if, in the aggregate, the changes in volume and price
represent no more than a 20 percent change in the maximum aggregate
offering price set forth in the “Calculation of Registration Fee” table in
the effective registration statement;
|
(iii) |
to
include any material information with respect to the plan of distribution
not previously disclosed in the registration statement or any material
change to such information in the registration
statement;
|
Provided,
however,
that
paragraphs (1)(i) and (1)(ii) above do not apply if the registration statement
is on Form S-3, Form S-8 or Form F-3, and the information required to be
included in a post-effective amendment by those paragraphs is contained in
periodic reports filed with or furnished to the Commission by the registrant
pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 that
are
incorporated by reference in the registration statement.
Provided,
however, that:
|
(A)
|
Paragraph
(1)(i) and (1)(ii) of this section do not apply if the registration
statement is on Form S-8, and the information required to be included
in a
post-effective amendment by those paragraphs is contained in the
reports
filed with or furnished to the Commission by the registrant pursuant
to
Section 13 or Section 15(d) of the Securities Exchange Act of 1934
(15
U.S.C. 78m or 78(d)) that are incorporated by reference in the
registration statement; and
|
|
(B)
|
Paragraphs
(1)(i), (1)(ii) and (1)(iii) of this section do not apply if the
registration statement is on Form S-3 or Form F-3 and the information
required to be included in a post-effective amendment by those paragraphs
is contained in reports filed with or furnished to the Commission
by the
registrant pursuant to Section 13 or Section 15(d) of the Securities
Exchange Act of 1934 that are incorporated by reference in the
registration statement, or is contained in a form of prospectus filed
pursuant to Rule 424(b) that is part of the registration
statement.
|
|
(C)
|
Provided
further, however,
that paragraphs (1)(i) and (1)(ii) do not apply if the registration
statement is for an offering of asset-backed securities on Form S-1
or
Form S-3, and the information required to be included in a post-effective
amendment is provided pursuant to Item 110(c) of Regulation
AB.
|
(2) |
That,
for purposes of determining any liability under the Securities Act
of
1933, each such post-effective amendment shall be deemed to be a
new
registration statement relating to the securities offered therein,
and the
offering of securities at that time shall be deemed to be the initial
bona
fide
offering thereof.
|
(3) |
To
remove from registration by means of a post-effective amendment any
of the
securities being registered which remain unsold at the termination
of the
offering.
|
(4) |
If
the registrant is a foreign private issuer, to file a post-effective
amendment of the registration statement to include any financial
statements required by Item 8.A. of Form 20-F at the start of any
delayed
offering or throughout a continuous offering. Financial statements
and
information otherwise required by Section 10(a)(3) of the Act need
not be
furnished, provided,
that the registrant includes in the prospectus, by means of a
post-effective amendment, financial statements required pursuant
to this
paragraph (4) and other information necessary to ensure that all
other
information in the prospectus is at least as current as the date
of those
financial statements. Notwithstanding the foregoing, with respect
to
registration statements on Form F-3, a post-effective amendment need
not
be filed to include financial statements and information required
by
Section 10(a)(3) of the Act or Rule 3-19 of this chapter if such
financial
statements and information are contained in periodic reports filed
with or
furnished to the Commission by the registrant pursuant to Section
13 or
Section 15(d) of the Securities Exchange Act of 1934 that are incorporated
by reference in the Form F-3.
|
(5) |
That,
for the purpose of determining liability under the Securities Act
of 1933
to any purchaser:
|
(i) If
the
registrant is relying on Rule 430B:
(A) Each
prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed
to
be part of the registration statement as of the date the filed prospectus was
deemed part of and included in the registration statement; and
(B) Each
prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7)
as
part of a registration statement in reliance on Rule 430B relating to an
offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose
of
providing the information required by Section 10(a) of the Securities Act of
1933 shall be deemed to be part of and included in the registration statement
as
of the earlier of the date such form of prospectus is first used after
effectiveness or the date of the first contract of sale of securities in the
offering described in the prospectus. As provided in Rule 430B, for liability
purposes of the issuer and any person that is at that date an underwriter,
such
date shall be deemed to be a new effective date of the registration statement
relating to the securities in the registration statement to which that
prospectus relates, and the offering of such securities at that time shall
be
deemed to be the initial bona
fide
offering
thereof. Provided,
however,
that no
statement made in a registration statement or prospectus that is part of the
registration statement or made in a document incorporated or deemed incorporated
by reference into the registration statement or prospectus that is part of
the
registration statement will, as to a purchaser with a time of contract of sale
prior to such effective date, supersede or modify any statement that was made
in
the registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such effective
date;
or
(ii) If
the
registrant is subject to Rule 430C, each prospectus filed pursuant to Rule
424(b) as part of a registration statement relating to an offering, other than
registration statements relying on Rule 430B or other than prospectuses filed
in
reliance on Rule 430A, shall be deemed to be part of and included in the
registration statement as of the date it is first used after effectiveness.
Provided,
however,
that no
statement made in a registration statement or prospectus that is part of the
registration statement or made in a document incorporated or deemed incorporated
by reference into the registration statement or prospectus that is part of
the
registration statement will, as to a purchaser with a time of contract of sale
prior to such first use, supersede or modify any statement that was made in
the
registration statement or prospectus that was part of the registration statement
or made in any such document immediately prior to such date of first
use.
(6) |
That,
for purposes of determining any liability of the registrant under
the
Securities Act of 1933 to any purchaser in the initial distribution
of
securities:
|
The
undersigned registrant undertakes that in a primary offering of securities
of
the undersigned registrant pursuant to this registration statement, regardless
of the underwriting method used to sell the securities to the purchaser, if
the
securities are offered or sold to such purchaser by means of any of the
following communications, the undersigned registrant will be a seller of the
purchaser and will be considered to offer or sell such securities to such
purchaser:
(i) Any
preliminary prospectus or prospectus of the undersigned registrant relating
to
the offering required to be filed pursuant to Rule 424;
(ii) Any
free
writing prospectus relating to the offering prepared by or on behalf of the
undersigned registrant or used or referred to by the undersigned
registrant;
(iii) The
portion of any other free writing prospectus relating to the offering containing
material information about the undersigned registrant or its securities provided
by or on behalf of the undersigned registrant; and
(iv) Any
other
communication that is an offer in the offering made by the undersigned
registrant to the purchaser.
The
undersigned registrant hereby undertakes that, for purposes of determining
any
liability under the Securities Act of 1933, each filing of the registrant’s
annual report pursuant to Section 13(a) or Section 15(d) of the
Securities Exchange Act of 1934 that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering
thereof.
Insofar
as indemnification for liabilities arising under the Securities Act of 1933
may
be permitted to directors, officers and controlling persons of the registrant
pursuant to the provisions described in Item 15 above, or otherwise, the
registrant has been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the
Securities Act of 1933, as amended, and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities (other than
the
payment by the registrant of expenses incurred or paid by a director, officer
or
controlling person of the registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person
in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the
Securities Act of 1933, as amended, and will be governed by the final
adjudication of such issue.
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the Registrant certifies
that
it has reasonable grounds to believe that it meets all of the requirements
for
filing on Form S-3 and has duly caused this Registration Statement to be signed
on its behalf by the undersigned, thereunto duly authorized, in the City of
Tarrytown, State of New York, on January 9, 2006.
PROGENICS
PHARMACEUTICALS, INC.
By:
/s/
Paul J. Maddon, M.D., Ph.D.
Paul
J.
Maddon, M.D., Ph.D.
Chief
Executive Officer and Chief Science Officer
POWER
OF ATTORNEY
KNOW
ALL
PERSONS BY THESE PRESENTS, that each of the persons whose names appear below
constitute and appoint Paul J. Maddon, M.D., Ph.D. and Robert A. McKinney,
and
each of them, his true and lawful attorney in fact and agent, with full power
of
substitution and resubstitution, for him and in his name, place and stead,
in
any and all capacities, to execute any and all amendments (including
post-effective amendments) to this Registration Statement (or any other
registration statement for the same offering that is to be effective upon filing
pursuant to Rule 462(b) under the Securities Act of 1933), and to file the
same,
together with all exhibits thereto, and other documents in connection therewith,
with the Securities and Exchange Commission, and such other agencies, offices
and persons as may be required by applicable law, granting unto said attorney
in
fact and agent, full power and authority to do and perform each and every act
and thing requisite or necessary to be done in and about the premises, as fully
to all intents and purposes as he might or could do in person, hereby ratifying
and confirming all that each said attorney-in-fact and agent may lawfully do
or
cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement
has been signed by the following persons in the capacities and on the dates
indicated.
Signature
|
Capacity
|
|
Date
|
/s/
Kurt W. Briner
Kurt
W. Briner
|
Co-Chairman
of the Board
|
|
January
9, 2006
|
/s/
Paul F. Jacobson
Paul
F. Jacobson
|
Co-Chairman
of the Board
|
|
January
9, 2006
|
/s/
Paul J. Maddon, M.D., Ph.D.
Paul
J. Maddon, M.D., Ph.D.
|
Chief
Executive Officer and Chief Science Officer(Principal Executive
Officer)
|
|
January
9, 2006
|
/s/
Robert A. McKinney
Robert
A. McKinney
|
Chief
Financial Officer, Vice President, Finance & Operations and Treasurer
(Principal Financial and Accounting Officer)
|
|
January
9, 2006
|
/s/
Charles A. Baker
Charles
A. Baker
|
Director
|
|
January
9, 2006
|
/s/
Mark F. Dalton
Mark
F. Dalton
|
Director
|
|
January
9, 2006
|
/s/
Stephen P. Goff, Ph.D.
Stephen
P. Goff, Ph.D.
|
Director
|
|
January
9, 2006
|
/s/
David A. Scheinberg, M.D., Ph.D.
David
A. Scheinberg, M.D., Ph.D.
|
Director
|
|
January
9, 2006
|
INDEX
TO EXHIBITS
Exhibit
Number
|
Description
of Exhibit
|
|
|
5.1
|
Opinion
of Dewey Ballantine LLP
|
23.1
|
Consent
of PricewaterhouseCoopers LLP
|
23.2
|
Consent
of Dewey Ballantine LLP (included in exhibit 5.1)
|
24.1
|
Power
of Attorney (included on the signature pages to this Registration
Statement).
|
______________
All
schedules have been omitted because they are not required or because the
required information is given in the Financial Statements or Notes thereto.